• Corpus ID: 19578674

Tagatose : The Multifunctional Food Ingredient and Potential Drug

  title={Tagatose : The Multifunctional Food Ingredient and Potential Drug},
  author={Sudhamani Muddada},
Diabetes and Obesity have reached epidemic proportions. The treatment of diabetes and Obesity includes life style change. The diet is recommended to be low calorie in order to reduce weight. A low calorie sweetner, tagatose has been approved for food usage since 2003. It is also awaiting clearance for its use as Antidiabetic agent. The review covers the history of tagatose, production and use as food ingredient and refers to its therapeutic potential as anti-diabetic and anti-obesity agent. The… 

Tables from this paper

D-Tagatose Is a Promising Sweetener to Control Glycaemia: A New Functional Food
D-tag is promising as a sweetener without major adverse effects observed in these clinical studies and eventually could be associated with important benefits for the treatment of obesity.
D-Tagatose as a Sucrose Substitute and Its Effect on the Physico-Chemical Properties and Acceptability of Strawberry-Flavored Yogurt
Sucrose reduction showed a positive effect on the purchase intent of the strawberry yogurts (an increase of 3–30%).
The rare sugar d-tagatose protects plants from downy mildews and is a safe fungicidal agrochemical
It is shown that d-tagatose controls a wide range of plant diseases and focus on downy mildews to analyze its mode of action and paves the way for the development of safe fungicidal agrochemicals using natural products.
Immobilized Trienzymatic System with Enhanced Stabilization for the Biotransformation of Lactose
Improvements in ketohexose productivities were achieved when the three single-immobilizates were incubated simultaneously with lactose in a mono-reactor system.


Tagatose, the new GRAS sweetener and health product.
  • G. V. Levin
  • Biology, Medicine
    Journal of medicinal food
  • 2002
The results, buttressed by the references cited, support the efficacy of the various applications disclosed for tagatose and suggest its synergism with high-intensity sweeteners also makes it useful in sodas.
Effect of Diets Containing Sucrose vs. D‐tagatose in Hypercholesterolemic Mice
It is demonstrated that in comparison to sucrose, equivalent substitution of TAG as dietary carbohydrate does not result in the same extent of obesity, hyperglycemia, hyperlipidemia, and atherosclerosis.
D‐tagatose, a novel hexose: acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes
Aim: D‐Tagatose (D‐tag), a hexose bulk sweetener, does not affect plasma glucose levels when orally administered to rodents. Additionally, D‐tag attenuates the rise in plasma glucose after mice are
Effects of acute and repeated oral doses of D-tagatose on plasma uric acid in normal and diabetic humans.
D-tagatose holds promise as a sweetener with no adverse clinical effects observed in these studies, and is associated with a slight decrease of plasma phosphorus and a slight increase of magnesium.
The acute effect of D-tagatose on food intake in human subjects
This present study suggests that d-tagatose may contribute to a reduced energy intake, and did not support any hyperphagic effect of d- tagatose, but rather suggests that the malabsorbed stereoisomer of fructose with potential application as a bulk sweetener should be added to the diet.
Sugar substitutes: their energy values, bulk characteristics, and potential health benefits.
D-Tagatose, a new candidate sweetener, is nearly as sweet as sucrose and has the bulk of sucrose, yet provides zero available energy, and potential contribution to human diet restriction along with its specific effect in delaying the aging effects of glycosylation is discussed.
Comparative gastrointestinal tolerance of sucrose, lactitol, or D-tagatose in chocolate.
It is demonstrated that a 20-g dose of D-tagatose is tolerated well in comparison to lactitol, and is associated with a significant increase in the frequency of passing feces, or in the number of subjects passing watery feces, in a double-blind, controlled crossover study.
Recent and Emerging Therapeutic Medications in Type 2 Diabetes Mellitus: Incretin-Based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol
Clinical data on the newly available incretin-based drugs on the market, including glucagon-like peptide agonists and of dipeptidyl peptidase type-4 inhibitors are reviewed, which can serve as an aid for clinicians to identify clinical indications in which these new agents can be applied in the treatment algorithm.
D-tagatose has low small intestinal digestibility but high large intestinal fermentability in pigs.
D-Tagatose served as a substrate for the microbiota in the cecum and proximal colon as indicated by a reduced pH, and a greater ATP concentration, adenylate energy charge (AEC) ratio and concentration of short-chain fatty acids, and the increase in the concentrations of propionate, butyrate and valerate suggests possible health benefits of this monosaccharide.
D-tagatose, a stereoisomer of D-fructose, increases blood uric acid concentration.
D-Tagatose attenuated the glycemic and insulinemic responses to a meal that was consumed 255 minutes after its administration, and both fructose and D-tagatose increased plasma concentrations of cholecystokinin and glucagon-like peptide-1 (GLP-1).